STOCKHOLM, March 17, 2014 - Karo Bio AB (publ) will be awarded 1 million SEK from Vinnova for the preclinical development of an ER-beta agonist for the treatment of multiple cancers. The grant is awarded through the Forska & Väx program to finance toxicity and safety pharmacology studies of an ERbeta agonist. In previous studies, the compound has been shown to significantly reduce tumor size in preclinical models of mesothelioma and other types of cancer with poor prognosis.
Help employers find you! Check out all the jobs and post your resume.
